Primary Care Network

The Role of CGRP in Migraine Therapy

In order to receive CME credit for this activity, please enter your name and address as indicated and answer the following questions. Your responses will be recorded and forwarded to Primary Care Network.

Name:
Degree:
Email:
Address:
City:
State:
Zip Code:
Phone:	xxx-xxx-xxxx
Fax:	xxx-xxx-xxxx

Post Test

Please answer the following questions by selecting the response you feel is correct for each question. Completion of this post-test will assist Primary Care Network in the measurement of educational outcomes. Thank you.

1. CGRP containing neurons are widely distributed in BOTH the central AND peripheral nervous systems.

A. T

B. F

2. Current research has suggested a role for CGRP in migraine due to its:

A. Effect on blood vessels (vasodilatory)

B. Effect on mast cells (degranulation)

C. Effect on pain transmission (central sensitization)

D. All of the above

E. None of the above

3. Clinical clues for a role of CGRP in headache include all of the following, EXCEPT:

A. Elevated levels in prolonged severe migraine

B. Elevated levels in adolescents with severe migraine

C. Decreased levels in tension-type headache

D. Elevated levels in cluster headache

4. Regarding the investigational intravenous CGRP antagonist BIBN 4096 BS (olcegepant) all of the following are true, EXCEPT:

A. A small Phase I study demonstrated prevention of h-aCGRP induced migraine by pretreatment with olcegepant

B. A single Phase II study showed olcegepant to have headache response and pain-free rates superior to placebo

C. Olcegepant sustained 24-hour pain-free rates were no better than placebo in the Phase II study

D. A Phase I safety and tolerability study of olcegepant in healthy volunteers showed a statistically significant increase in systolic blood pressure (+3 mmHg) compared to placebo (-10 mmHg)

5. A Phase II dose-finding study of the investigational oral CGRP antagonist MK-0974 (which compared MK-0974 to both placebo and 10 mg rizatriptan) showed all of the following EXCEPT:

A. The 300 mg and 600 mg doses of MK-0974 had 2-hour pain-relief efficacy numerically equivalent to rizatriptan

B. The 2-hour pain-free response for the 300 mg dose of MK-0974 was statistically superior to placebo and numerically superior to rizatriptan

C. The 24-hour sustained pain-free response for the 300 mg and 600 mg doses were statistically superior to placebo and numerically superior to rizatriptan

D. A linear dose response across all MK-0974 doses tested